AMH Cannot Be Increased in This Clinical Scenario
You cannot meaningfully increase AMH levels in a 36-year-old woman with endometriosis receiving Visanne (dienogest) treatment. AMH reflects ovarian reserve—the number of remaining follicles—and this declines naturally with age and is further compromised by endometriosis itself. No medical intervention, including stopping or modifying dienogest, can restore or increase ovarian reserve.
Understanding the Relationship Between Endometriosis, Dienogest, and AMH
Endometriosis Itself Reduces Ovarian Reserve
The disease process directly damages ovarian reserve independent of any treatment 1, 2:
- Women with endometriosis, particularly those over 30 years, have significantly lower AMH levels compared to healthy controls 1
- Stage III-IV endometriosis is associated with 40-48% lower AMH levels 2
- Ovarian endometriomas are most strongly associated with reduced AMH (54-61% lower levels), with even more pronounced effects in women with infertility 2
- Active disease is consistently associated with reduced ovarian reserve 1
Dienogest's Effect on AMH: The Evidence is Mixed but Shows Decline
Recent high-quality studies demonstrate that dienogest treatment is associated with AMH decline, though the magnitude varies:
- A 2025 prospective study showed dienogest caused a 21% median decline in AMH over 6 months, though this was less than surgery (38% decline) or oral contraceptives (26% decline) 3
- A 2024 study found significant AMH decline after 12 months of dienogest treatment (median -0.9 ng/mL, p=0.045), though no significant change was observed at 6 months 4
- Another 2024 study reported no significant changes in AMH levels during dienogest treatment for endometriomas ≥4 cm 5
The critical point: Even when AMH remains stable during dienogest treatment, it does not increase—at best, the decline may be slowed compared to other interventions.
What This Means for Clinical Management
If Fertility is the Concern
Prioritize fertility preservation NOW rather than attempting to increase AMH 6:
- Refer immediately to reproductive endocrinology for fertility evaluation and consideration of oocyte cryopreservation before any surgical intervention 6
- Consider medically assisted procreation (MAP) technology before undertaking endometriosis surgery, as surgery further depletes ovarian reserve 6
- Counsel the patient that delaying childbearing carries significant risk at age 36 with endometriosis 7
Regarding Dienogest Treatment
Continue dienogest if it is controlling pain symptoms effectively 8:
- Dienogest (a progestin) is effective for pain relief in endometriosis 8
- No medical therapy has been proven to affect future fertility in women with endometriosis 8
- Stopping dienogest will not increase AMH and may allow disease progression, potentially causing further ovarian damage 3
The Surgical Consideration
Avoid surgery for endometriomas unless absolutely necessary, as it causes the most significant AMH decline 6, 3:
- Bilateral cystectomy for endometrioma has harmful impact on ovarian reserve with postoperative fall in AMH 6
- Surgery shows 38% median AMH decline at 6 months 3
- First-line treatment should be medical in patients with pelvic pain and no immediate pregnancy project 6
Critical Pitfalls to Avoid
Do not stop dienogest hoping AMH will "recover"—the disease itself causes progressive ovarian reserve decline, and uncontrolled endometriosis may accelerate this 1, 3
Do not delay fertility evaluation—at 36 years with endometriosis, time is critical. Even expectant management shows progressive AMH decline (19% over 6 months) 3
Do not interpret stable AMH as "improvement"—AMH reflects remaining follicle pool, which only decreases with time. Stability during treatment is the best-case scenario.
Do not pursue surgery primarily to "improve fertility"—there is no evidence that surgical or medical therapy results in better fertility outcomes, and surgery causes the greatest AMH decline 8, 6, 3
The Bottom Line Algorithm
For a 36-year-old with endometriosis on dienogest:
- If fertility is desired: Immediate reproductive endocrinology referral → Consider oocyte cryopreservation → Continue medical management with dienogest
- If pain control is the goal: Continue dienogest (effective for pain, does not increase thrombotic risk, suitable for long-term use) 8, 9
- Monitor ovarian reserve: Check AMH and antral follicle count, but understand these guide fertility planning, not treatment decisions 7
- Personalize management based on patient's priorities: fertility preservation, pain control, or both 6
The harsh reality: AMH reflects biological age of the ovaries. At 36 with endometriosis, the focus must shift from increasing AMH (impossible) to preserving remaining fertility potential and managing symptoms effectively.